Cellectis S.A.: Barclays Still Sees 125% Price Potential After a Strong Quarterly Report!
Reading Time: 3 minutes
Cellectis S.A. (CLLS) is a clinical-stage biotechnology company that leverages its leading gene-editing platform to develop life-saving cell and gene therapies. The focus is on the allogeneic approach for CAR-T immunotherapies in oncology. This innovative concept enables the development of off-the-shelf gene-edited CAR-T cells to treat cancer patients, in contrast to autologous therapies, where cells must be extracted from each patient individually. The company controls the entire value chain of cell and gene therapy thanks to its own production...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
